An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.

ABSTRACT:

Background and purpose

Type 2 diabetes is one of the most severe chronic diseases and is an increasingly important public health problem worldwide. Several agonists of the glucagon-like peptide-1 (GLP-1) receptor have been developed to treat Type 2 diabetes but most of them are administered by injection. This mode of administration seriously reduces patient compliance and increases the risk of infection. Here, we describe the actions of a novel, orally available, GLP-1 receptor agonist - oral hypoglycaemic peptide 2 (OHP2) - derived from exendin-4 by replacing amino acids. We have also investigated its pharmacokinetic profiles, therapeutic effects and absorption mechanism.

Experimental approach

Healthy Wistar rats were used for pharmacokinetic analyses. In diabetic db/db mic

SUBMITTER: Lu W 

PROVIDER: S-EPMC7348098 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature